• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sandra Horning - Articles and news items

Roche logo

Roche’s Phase III study of Gazyva/Gazyvaro showed significant benefit in refractory indolent non-Hodgkin’s lymphoma

Industry news / 4 February 2015 / Roche

Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment…

Roche logo

Roche presents data for hemophilia A therapy ACE910

Industry news / 9 December 2014 / Roche

Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting…

Roche logo

FDA grants Priority Review for Lucentis in diabetic retinopathy

Industry news / 9 October 2014 / Roche

Roche announced that the U.S. Food and Drug Administration has accepted to file the company’s supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans…

Roche logo

Roche to present latest oncology advances during ESMO 2014 Congress

Industry news / 17 September 2014 / Roche

Roche announced that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain…

Roche logo

Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA)

Industry news / 15 September 2014 / Roche

Roche announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy, the advanced form of age-related macular degeneration, a progressive condition which can result in blindness…

Roche logo

FDA approves Roche’s Avastin plus chemotherapy for treatment of advanced cervical cancer

Industry news / 15 August 2014 / Roche

Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone…

Roche logo

Roche’s Gazyvaro approved in Europe for patients with the most common type of leukemia

Industry news / 29 July 2014 / Roche

Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy…

Roche logo

FDA grants Roche’s Avastin Priority Review for certain types of cervical cancer

Industry news / 15 July 2014 / Roche

Roche announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer…

Roche logo

Japan becomes first country to approve Roche’s alectinib for people with a specific form of advanced lung cancer

Industry news / 4 July 2014 / Roche

Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib…

Roche logo

CHMP recommends EU approval of Roche’s Avastin for platinum-resistant recurrent ovarian cancer

Industry news / 27 June 2014 / Roche

Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve the use of Avastin® (bevacizumab)…

Roche logo

CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia

Industry news / 23 May 2014 / Roche

Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukemia…

Roche logo

Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis

Industry news / 28 April 2014 / Roche

First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +